Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study
Por:
Roos, I, Sharmin, S, Ozakbas, S, Alroughani, R, Eichau, S, Grand'Maison, F, Boz, C, Lechner-Scott, J, Buzzard, K, Prat, A, Khoury, SJ, Grammond, P, van der Walt, A, Blanco, Y, Foschi, M, Soysal, A, Barnett, M, Prevost, J, Terzi, M, Gerlach, O, Macdonell, R, Sa, MJ, Spitaleri, D, Laureys, G, Van Pesch, V, John, N, Cartechini, E, Gouider, R, Maimone, D, Ramo-Tello, C, Hodgkinson, S, Slee, M, Mccombe, P, Garber, J, Sanchez-Menoyo, JL, Al-Asmi, A, Kermode, AG, Lapointe, E, Shaygannejad, V, Van Wijmeersch, B, Willekens, B, Castillo-Triviño, T, Taylor, B, Mathey, G, Le Page, E, De Seze, J, Ruet, A, Clavelou, P, Berger, E, Zephir, H, Kwiatkowski, A, Pelletier, J, Moreau, T, Labauge, P, Ciron, J, Lebrun-Frenay, C, Papeix, C, Defer, G, Laplaud, DA, Thouvenot, E, Stankoff, B, Maillart, E, Al-Khedr, A, Bourre, B, Casez, O, Dos Santos, A, Camdessanche, JP, Hankiewicz, K, Wahab, A, Cabre, P, Heinzlef, O, Pottier, C, Moulin, S, Magy, L, Labeyrie, C, Doghri, I, Vukusic, S and Kalincik, T
Publicada:
4 abr 2026
Ahead of Print:
1 abr 2026
Resumen:
Background and ObjectivesPatients aged >= 35 years at multiple sclerosis (MS) symptom onset with an Expanded Disability Status Scale (EDSS) score >= 3 within the first year are at highest risk of developing aggressive MS (EDSS >= 6 within 10 years). Patients without these features are at lowest risk. This study aimed to evaluate whether high-efficacy disease-modifying therapy (HE-DMT) reduced the risk of relapse and disability accumulation in individuals at high risk of aggressive MS, and whether treatment benefit varied by MS severity.MethodsThis observational cohort study used longitudinal data from two registries: MSBase (international) and OFSEP (France). Adults with relapse-onset MS and an EDSS score recorded within 12 months of symptom onset were included. Patients were classified into high-risk or low-risk groups for aggressive MS based on the above strata; those at intermediate risk were excluded. A pseudo-cohort framework compared periods of continuous HE-DMT (fingolimod, cladribine, monoclonal antibodies) with periods of non-HE-DMT states (on lower-efficacy DMTs or untreated) within each aggressive MS risk stratum. Marginal structural models with repeated adjustment for time-varying confounders of treatment and censoring were used to estimate counterfactual cumulative hazards of relapses and 6-month confirmed disability worsening and improvement. An interaction between MS risk stratum and treatment strategy was tested. A secondary analysis evaluated patients who received an HE-DMT during the study period.ResultsIn total, 10,405 people (2021 high risk, 8384 low risk) were included. Continuous HE-DMT reduced the risk of relapse in both high-risk and low-risk groups. There was no evidence of a difference in disability outcomes between treatment approaches. There was no evidence of an interaction between aggressive MS risk and treatment effect. In stratified analyses, lowest relapse risk was observed in the low-risk group treated with HE-DMT (hazard ratio [HR] 0.75, 95% CI 0.69-0.80). Treatment with HE-DMT was associated with relapse risk comparable to that observed in the low-risk group not treated with HE-DMT (HR 0.99, 0.87-1.13). In a secondary analysis restricted to patients who receive HE-DMT during the study timeframe, treatment with HE-DMT reduced the risk of disability worsening in the high-risk group (HR 0.75, 0.58-0.99), to the level observed in the low-risk group (HR 0.80, 0.70-0.92).ConclusionsHE-DMTs reduced the risk of relapse in people at both high and low risk of aggressive MS, with no evidence of differential treatment benefit. In the overall population, no evidence of a difference in disability outcomes between HE-DMT-treated and HE-DMT-untreated time was observed. However, among patients ever exposed to HE-DMT, disability worsening was less common while treated with HE-DMT.
Filiaciones:
Roos, I:
Royal Melbourne Hosp, Neuroimmunol Ctr, Dept Neurol, L7 635 Elizabeth St, Melbourne, Vic 3000, Australia
Univ Melbourne, Dept Med, CORE, Melbourne, Australia
Sharmin, S:
Univ Melbourne, Dept Med, CORE, Melbourne, Australia
Ozakbas, S:
Izmir Univ Econ, Med Point Hosp, Konak Izmir, Turkiye
Multiple Sclerosis Res Assoc, Izmir, Turkiye
Alroughani, R:
Amiri Hosp, Dept Med, Div Neurol, Sharq, Kuwait
Eichau, S:
Hosp Univ Virgen Macarena, Dept Neurol, Seville 41004, Spain
Grand'Maison, F:
Neuro Rive Sud, Greenfield Pk, PQ, Canada
Boz, C:
KTU, Farabi Hosp, Fac Med, Dept Neurol, Trabzon, Turkiye
Lechner-Scott, J:
Univ Newcastle, Hunter Med Res Inst, Newcastle, NSW, Australia
John Hunter Hosp, Hunter New England Hlth, Newcastle, NSW, Australia
Buzzard, K:
Box Hill Hosp, Dept Neurosci, Melbourne, Vic, Australia
Monash Univ, Eastern Hlth Clin Sch, Box Hill, Australia
Prat, A:
CHUM MS Ctr, Montreal, PQ, Canada
Univ Montreal, Montreal, PQ, Canada
Khoury, SJ:
Univ Montreal, Montreal, PQ, Canada
Grammond, P:
Amer Univ Beirut, Med Ctr, Nehme & Therese Tohme Multiple Sclerosis Ctr, Beirut, Lebanon
van der Walt, A:
CISSS ChaudiEre Appalache, Levis, PQ, Canada
Alfred Hosp, Dept Neurol, Melbourne, Australia
Blanco, Y:
Monash Univ, Sch Translat Med, Dept Neurosci, Melbourne, Australia
Foschi, M:
Hosp Clin Barcelona, Ctr Neuroimmunol, Serv Neurol, Barcelona, Spain
S Maria Croci Hosp Ravenna, Dept Neurosci, Neurol Unit, MS Ctr, Ravenna, Italy
Soysal, A:
Univ Aquila, Dept Biotechnol & Appl Clin Sci, Laquila, Italy
Barnett, M:
Bakirkoy Educ & Res Hosp Psychiat & Neurol Dis, Istanbul, Turkiye
Prevost, J:
Univ Sydney, Brain & Mind Ctr, Sydney, Australia
Terzi, M:
CSSS St Jerome, St Jerome, PQ, Canada
Gerlach, O:
19 Mayis Univ, Fac Med, Samsun, Turkiye
Zuyderland Med Ctr, Acad MS Ctr Zuyd, Dept Neurol, Sittard Geleen, Netherlands
Macdonell, R:
Maastricht Univ, Med Ctr, Sch Mental Hlth & Neurosci, Dept Neurol, Maastricht, Netherlands
Sa, MJ:
Austin Hlth, Melbourne, Australia
Ctr Hosp Univ Sao Joao, Dept Neurol, Porto, Portugal
Spitaleri, D:
Inst Invest Inovacao & Desenvolvimento Fernando Pe, FP I3ID, Porto, Portugal
Laureys, G:
Azienda Osped Rilievo Nazl San Giuseppe Moscati Av, Avellino, Italy
Van Pesch, V:
Univ Hosp Ghent, Dept Neurol, B-9000 Ghent, Belgium
Clin Univ St Luc, Dept Neurol, Brussels, Belgium
John, N:
Catholic Univ Louvain, Louvain La Neuve, Belgium
Monash Univ, Sch Clin Sci, Dept Med, Melbourne, Australia
Cartechini, E:
Monash Hlth, Dept Neurol, Clayton, Australia
Gouider, R:
AST Macerata, Neurol Unit, PO Unico Macerata, Macerata, Italy
Razi Univ Hosp, Clin Invest Ctr Neurosci & Mental Hlth, Dept Neurol, LR 18SP03, Tunis, Tunisia
Maimone, D:
Univ Tunis El Manar, Fac Med Tunis, Tunis, Tunisia
:
Azienda Osped Emergenza Cannizzaro, Ctr Sclerosi Multipla, UOC Neurol, Catania, Italy
Hodgkinson, S:
Hosp Badalona Germans Trias & Pujol, Dept Neurosci, Badalona, Spain
UNSW, Dept Med, Sydney, Australia
Slee, M:
Ingham Inst, Immune Tolerance Lab, Sydney, NSW, Australia
Mccombe, P:
UNSW, Dept Med, Sydney, Australia
Garber, J:
Flinders Univ Australia, Coll Med & Publ Hlth, Adelaide, Australia
Sanchez-Menoyo, JL:
Univ Queensland, Dept Neurol, Brisbane, Qld, Australia
Westmead Hosp, Dept Neurol, Sydney 2145, Australia
Al-Asmi, A:
Hosp Galdakao Usansolo, Dept Neurol, Galdakao 48960, Bizkaia, Spain
Kermode, AG:
Biocruces Bizkaia Hlth Res Inst, Baracaldo, Spain
Sultan Qaboos Univ, Coll Med & Hlth Sci, Muscat, Al Khodh, Oman
Univ Western Australia, Perron Inst Neurol & Translat Sci, Nedlands, Australia
Murdoch Univ, Ctr Mol Med & Innovat Therapeut, Perth, WA, Australia
Lapointe, E:
Murdoch Univ, Inst Immunol & Infect Dis, Perth, WA, Australia
Shaygannejad, V:
Univ Western Australia, Sir Charles Gairdner Hosp, Nedlands, WA 6009, Australia
Van Wijmeersch, B:
Ctr Hosp Univ Sherbrooke, Div Neurol, Med, Sherbrooke, PQ, Canada
Isfahan Univ Med Sci, Esfahan, Iran
Willekens, B:
Univ MS Ctr, Hasselt Pelt, Belgium
Pelt & Hasselt University, Noorderhart Rehabil & MS, Hasselt, Belgium
Antwerp Univ Hosp, Dept Neurol, Edegem, Belgium
Castillo-Triviño, T:
Univ Antwerp, Res Grp Translat Neurosci, Fac Med & Hlth Sci, Antwerp, Belgium
Taylor, B:
Univ Antwerp, Fac Med & Hlth Sci, Lab Expt Hematol, Antwerp, Belgium
Hosp Univ Donostia, San Sebastian, Spain
Mathey, G:
Royal Hobart Hosp, Hobart, Australia
Univ Tasmania, Menzies Inst Med Res, Hobart, Australia
Le Page, E:
Nancy Univ Hosp, Dept Neurol, Nancy, France
De Seze, J:
Univ Lorraine, APEMAC, Nancy, France
INSERM, CIC1414, Rennes, France
Ruet, A:
CHU Strasbourg, Dept Neurol, Strasbourg, France
Clavelou, P:
INSERM 1434, Strasbourg, France
Univ Hosp Bordeaux, Dept Neurol, Bordeaux, France
Berger, E:
CHU Clermont Ferrand, Dept Neurol, F-63003 Clermont Ferrand, France
Zephir, H:
Univ Clermont Auvergne, INSERM, Neurodol, Clermont Ferrand, France
Kwiatkowski, A:
CHU Besancon, Serv Neurol, Besancon, France
Pelletier, J:
Univ Lille, CHU Lille, CRCSEP Lille, Lille, France
Moreau, T:
Univ catholique Lille, Dept Neurol, GHICL, Lille, France
Labauge, P:
Aix Marseille Univ, Hop Timone, APHM, Pole Neurosci Clin, Marseille, France
Ciron, J:
CHU Dijon, Dept Neurol, Dijon, France
Montpellier Univ Hosp, Neurol Dept, Montpellier, France
Lebrun-Frenay, C:
CHU Toulouse, Dept Neurol, Toulouse, France
Papeix, C:
Univ Toulouse, CNRS, INSERM, Toulouse, France
Defer, G:
Univ Nice Cote Azur, CRCSEP, Serv Neurol, Nice, France
Laplaud, DA:
Fdn Rotschild, Dept Neurol, F-75005 Paris, France
Thouvenot, E:
Caen Univ Hosp, Dept Neurol, Caen, France
Nantes Univ, CHU Nantes, INSERM,CIC INSERM 1413, Ctr Res Transplantat & Translat Immunol,UMR 1064, F-44000 Nantes, France
Stankoff, B:
Univ Hosp Nimes, Dept Neurol, Nimes, France
Maillart, E:
Univ Montpellier, Inserm, CESP, Montpellier, France
Al-Khedr, A:
Sorbonne Univ, UPMC Univ Paris UMR S 1127 06, Hop Pitie Salpetriere,Inserm U1127,CNRS UMR 7225, AP HP,Inst Cerveau & Moelle Epiniere ICM,Dept Gen, F-75000 Paris, France
Bourre, B:
Hop La Pitie Salpetriere, Dept Neurol, Paris, France
Casez, O:
CHU Amiens, Dept Neurol, F-80000 Amiens, France
Dos Santos, A:
CHU Rouen, Dept Neurol, F-76000 Rouen, France
Camdessanche, JP:
Univ Grenoble Alpes, Grenoble Alpes Univ Hosp, Dept Neurol,CHU Grenoble Alpes, Neurol MS Clin Grenoble,La Tronche T RAIG,TIMC IMA, F-38700 Grenoble, France
Hankiewicz, K:
CHU La Mil, Hop Jean Bernard, Dept Neurol, F-86000 Poitiers, France
Wahab, A:
CHU St Etienne, Dept Neurol, St Etienne, France
Cabre, P:
Ctr Hosp St Denis, Dept Neurol, Hop Pierre Delafontaine, F-93200 St Denis, France
Heinzlef, O:
Hop Henri Mondor, APHP, Dept Neurol, F-94000 Creteil, France
Pottier, C:
CHU Martinique, Dept Neurol, Fort De France, Martinique, France
Moulin, S:
Hop Poissy St Germain En Laye, Poissy, France
Magy, L:
Hop Rene Dubos, Dept Neurol, CH Pontoise, Pontoise, France
Labeyrie, C:
CHU Reims, CRC SEP, Dept Neurol, F-51092 Reims, France
Doghri, I:
CHU Limoges, Hop Dupuytren, Dept Neurol, F-87000 Limoges, France
Vukusic, S:
CHU Bicetre, Dept Neurol, F-94275 Le Kremlin Bicetre, France
CHU Tours, CRC SEP, Hop Bretonneau, F-37000 Tours, France
Hosp Civils Lyon, Serv Neurol sclerose plaques pathol myeline & Neur, Lyon, France
Ctr Rech Neurosci Lyon, Observ Francais Sclerose Plaques, INSERM 1028, Lyon, France
Kalincik, T:
Royal Melbourne Hosp, Neuroimmunol Ctr, Dept Neurol, L7 635 Elizabeth St, Melbourne, Vic 3000, Australia
Univ Melbourne, Dept Med, CORE, Melbourne, Australia
Univ Lyon, Lyon, France
Eugene Devic EDMUS Fdn Multiple Sclerosis, Lyon, France
Green Submitted, hybrid
|